Heat shock protein 90: Translation from cancer to Alzheimer's disease treatment?

BMC Neuroscience

Volumn 9, Issue SUPPL. 2, 2008, Pages

  Luo, Wenjie ^a   Rodina, Anna ^b   Chiosis, Gabriela ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANAPLASTIC LYMPHOMA KINASE; ANDROGEN RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASEIN KINASE I; CD135 ANTIGEN; CD36 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CYCLIN DEPENDENT KINASE 5; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOPHOSMIN; PROTEIN KINASE B; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; PROTEIN P25; PROTEIN P35; RAF PROTEIN; TANESPIMYCIN; TAU PROTEIN; UNINDEXED DRUG; CHAPERONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; GENE MUTATION; HUMAN; INFLAMMATION; KENNEDY DISEASE; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; NEOPLASM; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; TAUOPATHY; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; NEOPLASMS; NERVE DEGENERATION;

EID: 57449113371     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-9-S3-S7     Document Type: Conference Paper

References (69)

1. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9 10647931
2. Xu W Neckers L Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells Clin Cancer Res 2007, 13:1625-1629. 10.1158/ 1078-0432.CCR-06-2966 17363512
3. Kamal A Boehm MF Burrows FJ Therapeutic and diagnostic implications of Hsp90 activation Trends Mol Med 2004, 10:283-290. 10.1016/ j.molmed.2004.04.006 15177193
4. Chiosis G Modulating chaperones in transformed systems - a focus on Hsp90 and cancer Expert Opin Ther Targets 2006, 10:37-50. 10.1517/ 14728222.10.1.37 16441227
5. Whitesell L Lindquist SL HSP90 and the chaperoning of cancer Nat Rev Cancer 2005, 10:761-772. 10.1038/nrc1716
6. Workman P Burrows F Neckers L Rosen N Drugging the cancer chaperone HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress Ann N Y Acad Sci 2007, 1113:202-216. 10.1196/ annals.1391.012 17513464
7. Mimnaugh EG Chavany C Neckers L Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin J Biol Chem 1996, 271:22796-22801. 10.1074/ jbc.271.9.4974 8798456
8. Xu Y Lindquist S Heat-shock protein Hsp90 governs the activity of pp60v-src kinase Proc Natl Acad Sci USA 1993, 90:7074-7078. 47078 7688470 10.1073/pnas.90.15.7074
9. Blagosklonny MV Toretsky J Bohen S Neckers L Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90 Proc Natl Acad Sci USA 1996, 93:8379-8383. 38679 8710879 10.1073/pnas.93.16.8379
10. Nimmanapalli R O'Bryan E Bhalla K Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr- Abl-positive human leukemic blasts Cancer Res 2001, 61:1799-1804. 11280726
11. Gorre ME Ellwood-Yen K Chiosis G Rosen N Sawyers CL BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 Blood 2002, 100:3041-3044. 10.1182/ blood-2002-05-1361 12351420
12. Bonvini P Gastaldi T Falini B Rosolen A Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin Cancer Res 2002, 62:1559-1566. 11888936
13. George P Bali P Cohen P Tao J Guo F Sigua C Vishvanath A Fiskus W Scuto A Annavarapu S Moscinski L Bhalla K Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3 Cancer Res 2004, 64:3645-3652. 10.1158/ 0008-5472.CAN-04-0006 15150124
14. Beliakoff J Bagatell R Paine-Murrieta G Taylor CW Lykkesfeldt AE Whitesell L Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors Clin Cancer Res 2003, 9:4961-4971. 14581371
15. Solit DB Zheng FF Drobnjak M Münster PN Higgins B Verbel D Heller G Tong W Cordon-Cardo C Agus DB Scher HI Rosen N 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/NEU and inhibits the growth of prostate cancer xenografts Clin Cancer Res 2002, 8:986-993. 12006510
16. Shimamura T Lowell AM Engelman JA Shapiro GI Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins Cancer Res 2005, 65:6401-6408. 10.1158/ 0008-5472.CAN-05-0933 16024644
17. Castro JE Prada CE Loria O Kamal A Chen L Burrows FJ Kipps TJ ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: Inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia Blood 2005, 106:2506-2512. 1895276 15972449 10.1182/blood-2005-03-1099
18. Maloney A Workman P HSP90 as a new therapeutic target for cancer therapy: The story unfolds Expert Opin Biol Ther 2002, 2:3-24. 10.1517/ 14712598.2.1.3 11772336
19. Klettner A The induction of heat shock proteins as a potential strategy to treat neurodegenerative disorders Drug News Perspect 2004, 17:299-306. 10.1358/dnp.2004.17.5.829033 15334179
20. Barral JM Broadley SA Schaffar G Hartl FU Roles of molecular chaperones in protein misfolding diseases Semin Cell Dev Biol 2004, 15:17-29. 10.1016/j.semcdb.2003.12.010 15036203
21. Soti C Nagy E Giricz Z Vigh L Csermely P Ferdinandy P Heat shock proteins as emerging therapeutic targets Br J Pharmacol 2005, 146:769-780. 1751210 16170327 10.1038/sj.bjp.0706396
22. Zou J Guo Y Guettouche T Smith DF Voellmy R Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1 Cell 1998, 94:471-480. 10.1016/ S0092-8674(00)81588-3 9727490
23. Waza M Adachi H Katsuno M Minamiyama M Sang C Tanaka F Inukai A Doyu M Sobue G 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration Nat Med 2005, 11:1088-1095. 10.1038/nm1298 16155577
24. Thomas M Harrell JM Morishima Y Peng HM Pratt WB Lieberman AP Pharmacologic and genetic inhibition of Hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction Hum Mol Genet 2006, 15:1876-1883. 10.1093/hmg/ddl110 16644868
25. Luo W Dou F Rodina A Chip S Kim J Zhao Q Moulick K Aguirre J Wu N Greengard P Chiosis G Roles of heat shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies Proc Natl Acad Sci USA 2007, 104:9511-9516. 1890525 17517623 10.1073/ pnas.0701055104
26. Dickey CA Kamal A Lundgren K Klosak N Bailey RM Dunmore J Ash P Shoraka S Zlatkovic J Eckman CB Patterson C Dickson DW Nahman NS Jr Hutton M Burrows F Petrucelli L The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J Clin Invest 2007, 117:648-658. 1794119 17304350 10.1172/JCI29715
27. Adachi H Waza M Katsuno M Tanaka F Doyu M Sobue G Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy Neuropathol Appl Neurobiol 2007, 33:135-151. 10.1111/ j.1365-2990.2007.00830.x 17359355
28. Murray B Lynch T Farrell M Clinicopathological features of the tauopathies Biochem Soc Trans 2005, 33:595-599. 10.1042/BST0330595 16042552
29. Kosik KS Shimura H Phosphorylated tau and the neurodegenerative foldopathies Biochim Biophys Acta 2005, 1739:298-310. 15615647
30. Brandt R Leschik J Functional interactions of tau and their relevance for Alzheimer's disease Curr Alzheimer Res 2004, 1:255-269. 10.2174/ 1567205043332054 15975055
31. Dermaut B Kumar-Singh S Rademakers R Theuns J Cruts M Van Broeckhoven C Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum Trends Genet 2005, 21:664-672. 10.1016/j.tig.2005.09.005 16221505
32. Lau LF Schachter JB Seymour PA Sanner MA Tau protein phosphorylation as a therapeutic target in Alzheimer's disease Curr Top Med Chem 2002, 4:395-415. 10.2174/1568026024607526
33. Chiosis G Discovery and development of purine-scaffold Hsp90 inhibitors Curr Top Med Chem 2006, 6:1183-1191. 10.2174/156802606777812013 16842155
34. Hardy J Testing times for the 'amyloid cascade hypothesis' Neurobiol Aging 2002, 23:1073-1074. 10.1016/S0197-4580(02)00042-8 12470803
35. Jarrett JT Berger EP Lansbury PT Jr The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease Biochemistry 1993, 32:4693-4697. 10.1021/bi00069a001 8490014
36. Lee KY Clark AW Rosales JL Chapman K Fung T Johnston RN Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain Neurosci Res 1999, 34:21-29. 10.1016/S0168-0102(99)00026-7 10413323
37. Baumann K Mandelkow EM Biernat J Piwnica-Worms H Mandelkow E Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5 FEBS Lett 1993, 336:417-424. 10.1016/ 0014-5793(93)80849-P 8282104
38. Tsai LH Delalle I Caviness VS Jr Chae T Harlow E p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5 Nature 1994, 371:419-423. 10.1038/371419a0 8090221
39. Tseng HC Zhou Y Shen Y Tsai LH A survey of cdk5 activator p35 and p25 levels in Alzheimer's disease brains FEBS Lett 2002, 523:58-62. 10.1016/ S0014-5793(02)02934-4 12123804
40. Lee MS Kwon YT Li M Peng J Friedlander RM Tsai LH Neurotoxicity induces cleavage of p35 to p25 by calpain Nature 2000, 405:360-364. 10.1038/ 35012636 10830966
41. Ahlijanian MK Barrezueta NX Williams RD Jakowski A Kowsz KP McCarthy S Coskran T Carlo A Seymour PA Burkhardt JE Nelson RB McNeish JD Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5 Proc Natl Acad Sci USA 2000, 97:2910-2915. 16029 10706614 10.1073/pnas.040577797
42. Cruz JC Kim D Moy LY Dobbin MM Sun X Bronson RT Tsai LH p25/ cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo J Neurosci 2006, 26:10536-10541. 10.1523/JNEUROSCI.3133-06.2006 17035538
43. Hashiguchi M Saito T Hisanaga S Hashiguchi T Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau J Biol Chem 2002, 277:44525-44530. 10.1074/jbc.M207426200 12226093
44. Iijima K Ando K Takeda S Satoh Y Seki T Itohara S Greengard P Kirino Y Nairn AC Suzuki T Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5 J Neurochem 2000, 75:1085-1091. 10.1046/j.1471-4159.2000.0751085.x 10936190
45. Lee MS Kao SC Lemere CA Xia W Tseng HC Zhou Y Neve R Ahlijanian MK Tsai LH APP processing is regulated by cytoplasmic phosphorylation J Cell Biol 2003, 163:83-95. 2173445 14557249 10.1083/jcb.200301115
46. Cruz JC Tsai LH Cdk5 deregulation in the pathogenesis of Alzheimer's disease Trends Mol Med 2004, 10:452-458. 10.1016/j.molmed.2004.07.001 15350898
47. Phiel CJ Wilson CA Lee VM Klein PS GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 2003, 423:435-439. 10.1038/nature01640 12761548
48. Flajolet M He G Heiman M Lin A Nairn AC Greengard P Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I Proc Natl Acad Sci USA 2007, 104:4159-4164. 1820725 17360493 10.1073/ pnas.0611236104
49. Venezia V Nizzari M Carlo P Corsaro A Florio T Russo C Amyloid precursor protein and presenilin involvement in cell signaling Neurodegener Dis 2007, 4:101-111. 10.1159/000101834 17596704
50. Ballatore C Lee VM Trojanowski JQ Tau-mediated neurodegeneration in Alzheimer's disease and related disorders Nat Rev Neurosci 2007, 8:663-672. 10.1038/nrn2194 17684513
51. Blurton-Jones M Laferla FM Pathways by which Abeta facilitates tau pathology Curr Alzheimer Res 2006, 3:437-448. 10.2174/156720506779025242 17168643
52. Churcher I Tau therapeutic strategies for the treatment of Alzheimer's disease Curr Top Med Chem 2006, 6:579-595. 10.2174/156802606776743057 16712493
53. McGeer PL Rogers J McGeer EG Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years J Alzheimers Dis 2006, 9(3 Suppl):271-276. 16914866
54. Cole GM Morihara T Lim GP Yang F Begum A Frautschy SA NSAID and antioxidant prevention of Alzheimer's disease: Lessons from in vitro and animal models Ann N Y Acad Sci 2004, 1035:68-84. 10.1196/annals.1332.005 15681801
55. Akiyama H Barger S Barnum S Bradt B Bauer J Cole GM Cooper NR Eikelenboom P Emmerling M Fiebich BL Finch CE Frautschy S Griffin WS Hampel H Hull M Landreth G Lue L Mrak R Mackenzie IR McGeer PL O'Banion MK Pachter J Pasinetti G Plata-Salaman C Rogers J Rydel R Shen Y Streit W Strohmeyer R Tooyoma I Van Muiswinkel FL Veerhuis R Walker D Webster S Wegrzyniak B Wenk G Wyss-Coray T Inflammation and Alzheimer's disease Neurobiol Aging 2000, 21:383-421. 10.1016/S0197-4580(00)00124-X 10858586
56. Ho GJ Drego R Hakimian E Masliah E Mechanisms of cell signaling and inflammation in Alzheimer's disease Curr Drug Targets Inflamm Allergy 2005, 4:247-256. 10.2174/1568010053586237 15853747
57. Kitazawa M Oddo S Yamasaki TR Green KN LaFerla FM Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease J Neurosci 2005, 25:8843-8853. 10.1523/ JNEUROSCI.2868-05.2005 16192374
58. Masliah E Mallory M Alford M DeTeresa R Hansen LA McKeel DW Jr Morris JC Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease Neurology 2001, 56:127-129. 11148253
59. Kim Y Sung JY Ceglia I Lee KW Ahn JH Halford JM Kim AM Kwak SP Park JB Ho Ryu S Schenck A Bardoni B Scott JD Nairn AC Greengard P Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology Nature 2006, 442:814-817. 10.1038/nature04976 16862120
60. Fischer A Sananbenesi F Pang PT Lu B Tsai LH Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory Neuron 2005, 48:825-838. 10.1016/ j.neuron.2005.10.033 16337919
61. Shen Y He P Zhong Z McAllister C Lindholm K Distinct destructive signal pathways of neuronal death in Alzheimer's disease Trends Mol Med 2006, 12:574-579. 10.1016/j.molmed.2006.10.002 17055782
62. Takashima A GSK-3 is essential in the pathogenesis of Alzheimer's disease J Alzheimers Dis 2006, 9(3 Suppl):309-317. 16914869
63. Sekine Y Takeda K Ichijo H The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases Curr Mol Med 2006, 6:87-97. 10.2174/ 156652406775574541 16472116
64. Monaco EA 3rd Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease Curr Alzheimer Res 2004, 1:33-38. 10.2174/ 1567205043480519 15975083
65. Lee JH Kim HS Lee SJ Kim KT Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death J Cell Sci 2007, 120:2259-2271. 10.1242/jcs.03468 17591690
66. McShea A Lee HG Petersen RB Casadesus G Vincent I Linford NJ Funk JO Shapiro RA Smith MA Neuronal cell cycle re-entry mediates Alzheimer disease-type changes Biochim Biophys Acta 2007, 1772:467-472. 17095196
67. Woods J Snape M Smith MA The cell cycle hypothesis of Alzheimer's disease: Suggestions for drug development Biochim Biophys Acta 2007, 1772:503-508. 17223322
68. Hamdane M Buée L The complex p25/Cdk5 kinase in neurofibrillary degeneration and neuronal death: The missing link to cell cycle Biotechnol J 2007, 2:967-977. 10.1002/biot.200700059 17571276
69. Powers MV Workman P Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocr Relat Cancer 2006, (Suppl 1):S125-S135. 10.1677/erc.1.01324